Genmab — Juni 2023
-
Donation med stor tak for al den gode information, som tilflyder mig. https://www.proinvestor.com/support
-
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma https://www.jnj.com/janssen-presents-longer-term-talquetamab-follow-up-data-showing-overall-response-rates-of-more-than-70-percent-in-heavily-pretreated-patients-with-multiple-myeloma
-
TRiMM-2: Response Rate of 78% Seen in Patients Who Receive Talquetamab With Subcutaneous Daratumumab for Multiple Myleoma https://www.ajmc.com/view/trimm-2-response-rate-of-78-seen-in-patients-who-receive-talquetamab-with-subcutaneous-daratumumab-for-multiple-myleoma
-
Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Updated TRIMM-2 Results https://www.congresshub.com/Oncology/AM2023/Talquetamab/Dholaria
-
Dual Bispecific Combination Teclistamab/Talquetamab Displays High Activity in RRMM https://www.targetedonc.com/view/dual-bispecific-combination-teclistamab-talquetamab-displays-high-activity-in-rrmm
-
-
First Results From the RedirecTT-1 Study With Teclistamab + Talquetamab Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma https://www.congresshub.com/Oncology/AM2023/Teclistamab/Cohen
-
-
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT
(amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer -
-
the amivantamab posters are now all available https://www.congresshub.com/Oncology/AM2023
-
SC dosing of amivantamab significantly improved IRR safety profile (16% vs 67% for IV) https://www.congresshub.com/Oncology/AM2023/Amivantamab/Minchom#interactive_pdf That should make this drug much much more tolerable
-
another Hemophilia trial for Daratumumab ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor https://www.clinicaltrials.gov/ct2/show/NCT05888870
-
Janssen Presents Longer-Term Data for TECVAYLI
(teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma https://www.jnj.com/janssen-presents-longer-term-data-for-tecvayli-teclistamab-cqyv-showing-a-duration-of-response-of-22-months-in-patients-with-relapsed-or-refractory-multiple-myeloma -
J&J’s multiple myeloma combo produces déjà vu with 96% Carvykti-like response https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response
Det er i 1L ?Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind